The Role of Gut Microbiome in the Pathogenesis and the Treatment of Inflammatory Bowel Diseases
- PMID: 38516478
- PMCID: PMC10957260
- DOI: 10.7759/cureus.54569
The Role of Gut Microbiome in the Pathogenesis and the Treatment of Inflammatory Bowel Diseases
Abstract
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic condition characterized by inflammation of the gastrointestinal tract. Its exact cause is unknown, but it's thought to result from a dysregulated immune response influenced by various factors, including changes in the intestinal microbiota, diet, lifestyle, and genetics. The gut microbiome, consisting of diverse microorganisms, plays a crucial role in maintaining physiological balance, with its disruption leading to inflammatory responses typical of IBD. Treatments primarily aim at symptom control, employing immunomodulators, corticosteroids, and newer approaches like probiotics, prebiotics, fecal transplants, and dietary modifications, all focusing on leveraging the microbiota's potential in disease management. These strategies aim to restore the delicate balance of the gut microbiome, typically altered in IBD, marked by a decrease in beneficial bacteria and an increase in harmful pathogens. This review underscores the importance of the gut microbiome in the pathogenesis and treatment of IBD, highlighting the shift towards personalized medicine and the necessity for further research in understanding the complex interactions between the gut microbiota, immune system, and genetics in IBD. It points to the potential of emerging treatments and the importance of a multifaceted approach in managing this complex and challenging disease.
Keywords: gut microbiome; ibd; immune dysregulation; inflammatory bowel disease; treatment strategies.
Copyright © 2024, Vidal-Gallardo et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures

Similar articles
-
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).Int J Mol Sci. 2025 Mar 11;26(6):2503. doi: 10.3390/ijms26062503. Int J Mol Sci. 2025. PMID: 40141145 Free PMC article. Review.
-
The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.Microbiol Spectr. 2015 Jun;3(3). doi: 10.1128/microbiolspec.MBP-0008-2014. Microbiol Spectr. 2015. PMID: 26185088
-
Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome.Cureus. 2024 Jul 22;16(7):e65136. doi: 10.7759/cureus.65136. eCollection 2024 Jul. Cureus. 2024. PMID: 39170992 Free PMC article. Review.
-
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.Int J Mol Sci. 2025 Mar 27;26(7):3059. doi: 10.3390/ijms26073059. Int J Mol Sci. 2025. PMID: 40243712 Free PMC article. Review.
-
Cross-talk between macrophages and gut microbiota in inflammatory bowel disease: a dynamic interplay influencing pathogenesis and therapy.Front Med (Lausanne). 2024 Sep 16;11:1457218. doi: 10.3389/fmed.2024.1457218. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39355844 Free PMC article. Review.
Cited by
-
Chinese herbal medicine-derived extracellular vesicles as novel biotherapeutic tools: present and future.J Transl Med. 2024 Nov 25;22(1):1059. doi: 10.1186/s12967-024-05892-3. J Transl Med. 2024. PMID: 39587576 Free PMC article. Review.
References
-
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Ng SC, Shi HY, Hamidi N, et al. Lancet. 2017;390:2769–2778. - PubMed
-
- Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. Sharara AI, Al Awadhi S, Alharbi O, et al. Expert Rev Gastroenterol Hepatol. 2018;12:883–897. - PubMed
Publication types
LinkOut - more resources
Full Text Sources